Quickly & safely dissolve thrombus with the EKOS® System.

Treat smarter. Achieve more.

The Acoustic Pulse Difference

EKOS® Acoustic Pulse Thrombolysis™ is a minimally invasive system for dissolving thrombus. The ultrasonic core generates a localized acoustic field that targets the entire thrombus. This greatly accelerates lytic dispersion by driving the drug deeper into the clot and unwinding the fibrin to expose plasminogen receptor sites.

Acoustic Pulse Thrombolysis™:
- Speeds time-to-dissolution.
- Results in quality clinical outcomes.
- Lowers the risk of bleeding and other complications1,4; increases thrombus removal and clinical improvement compared to either standard CDT or thrombectomy.1,5

More Effective Drug Delivery:
- Reduces dosage requirements by as much as 68% compared to standard CDT.4
- Requires up to 4x less drug dosage than systemic delivery.6,7

Superior Thrombus Clearance2,4:
- 48% greater drug absorption within 1 hour.8
- 84% greater drug absorption within 2 hours.8

The Thrombosis Barrier

Tightly wound fibrin prevents lytic dispersion to receptor sites.

With Acoustic Pulse

Ultrasonic energy thins fibrin and exposes receptor sites.

With Acoustic Pulse + Lytic

More drug reaches entire thrombus, accelerating absorption.

Since its beginning, EKOS® has had one goal: develop life-enhancing and lifesaving endovascular treatments for vascular thrombosis. EKOS® is committed to developing device-based therapies that improve patient outcomes, lower risks and improve treatment predictability.

The EKOS® System’s targeted ultrasound waves accelerate thrombus dissolution by unwinding the fibrin matrix.
Deep Vein Thrombosis

The EkoSonic® Endovascular System dissolves thrombus more completely even behind valves and IVC filters. It quickly restores blood flow, potentially reducing the risk of pulmonary embolism and post-thrombotic syndrome (PTS). Approximately 50% of patients with acute ilio-femoral DVT develop PTS. A low-dose lytic and EKOS® regimen has been associated with a low-bleeding rate and high venous patency with 90% of patients experiencing no DVT complications.

Peripheral Arterial Occlusion

The EkoSonic® Endovascular System improves on standard CDT by safely accelerating drug penetration, even in difficult-to-reach areas. Compared to traditional CDT the EkoSonic® Endovascular System offers:

- Shorter treatment times
- Higher dissolution rate of entire thrombus (95.3% vs. 66.7%, p=0.002)
- Lower bleeding rates (4.7% vs. 23.8%, p=0.026)
- Lower 30-day amputation rate (19.5% vs. 42.9%, p=0.04)
- Shorter hospital stays (5.7 vs. 8.3 days, p=0.027)

Treatment for PE, DVT & PAO

Pulmonary Embolism

The EkoSonic® Endovascular System is the only endovascular device cleared by the FDA for the treatment of pulmonary embolism. The current standard of care, anti-coagulation, does not resolve existing thrombus. EKOS® has been shown to yield safe and effective results for acute, massive and submassive PE. It improves right ventricular function and pulmonary artery pressure while minimizing the risk of bleeding.

In the Seattle II study of 150 patients with massive or submassive PE using an EKOS® and lytic combination, the mean RV/LV ratio decreased from 1.55 pre-procedure to 1.13 at 48 hours post-procedure (P<0.0001) while PA systolic pressure deceased from 51.4 mm Hg to 36.9 mm Hg (P<0.0001). In contrast to the 2.5–3% rate of intracranial hemorrhaging associated with historical systemic fibrinolysis and full-dose tPA, no patients in this study experienced intracranial bleeding or fatal bleeding events.

Deep Vein Thrombosis

The EkoSonic® Endovascular System dissolves thrombus more completely even behind valves and IVC filters. It quickly restores blood flow, potentially reducing the risk of pulmonary embolism and post-thrombotic syndrome (PTS). Approximately 50% of patients with acute ilio-femoral DVT develop PTS. A low-dose lytic and EKOS® regimen has been associated with a low-bleeding rate and high venous patency with 90% of patients experiencing no DVT complications.

Peripheral Arterial Occlusion

The EkoSonic® Endovascular System improves on standard CDT by safely accelerating drug penetration, even in difficult-to-reach areas. Compared to traditional CDT the EkoSonic® Endovascular System offers:

- Shorter treatment times
- Higher dissolution rate of entire thrombus (95.3% vs. 66.7%, p=0.002)
- Lower bleeding rates (4.7% vs. 23.8%, p=0.026)
- Lower 30-day amputation rate (19.5% vs. 42.9%, p=0.04)
- Shorter hospital stays (5.7 vs. 8.3 days, p=0.027)
Patients stricken with a life-threatening pulmonary embolism can be successfully and safely treated with EKOS.®

Samuel Z. Goldhaber, MD.
Professor of Medicine, Harvard Medical School
Director, Thrombosis Research Group, Brigham and Women’s Hospital
Lower patient risk. Higher procedure predictability.

Targeting the Thrombus, Safely

With EKOS® Acoustic Pulse Thrombolysis, you can typically use less lytic and most of the drug remains in the thrombus. It dissolves the thrombus without damaging vessels, valves or walls. There is no mechanical disruption resulting in distal embolization.

The EKOS® System’s safety and efficacy is supported by Level 1 and Level 2 data.

Reduced Procedure Time

EKOS® requires significantly shorter treatment times, typically only 33–50% of standard CDT. Unlike more complex surgical solutions, EKOS® is an efficient, three-step process:

1) Insertion of the EKOS® 5.4 F infusion catheter to the treatment site.
2) Insertion of the ultrasonic core until it locks in place.
3) Activation of the acoustic pulse and lytic drip.

You can precisely match treatment to thrombus length with treatment zones ranging from 6cm to 50cm. Radiopaque marker bands at each end of the treatment zone enhance visualization. The control unit’s interface allows for easy setting optimization as lysis progresses. At-a-glance operating status, alarms and treatment times are easy to read from a distance.

EKOS has procedure-based expertise and 24/7 helpline support. We can help you lower the threshold of predictability from table through ICU.

The EkoSonic Endovascular System includes an ultrasonic core within an infusion catheter, a control unit and a cart with universal power supply.
The fast, safe solution for vascular thrombosis.

The EkoSonic® Endovascular System:

- Quality clinical outcomes
- Predictable results
- Minimized bleeding risk
- Efficient procedures
- 24/7 helpline support

The EKOS® effect (in green) changes the standard of care for pulmonary embolism and dissolves the thrombus more completely, even in difficult-to-reach areas for deep vein thrombosis and peripheral arterial occlusion.

- Reduces RV/LV ratio by more than 25% on average\(^7\)
- Reduces PA pressures by 28% (at 48 hours)\(^7\)
- 76% less thrombolytic drug dosage than standard treatment\(^7\)
- Minimized risk of bleeding\(^6\)

- 50% of DVT patients have PE\(^10\)
- Removes thrombus more completely compared to CDT\(^16\)
- Reduce post-thrombotic syndrome\(^11\)

- Lower 30-day amputation rate\(^2\)
- Lower bleeding rates when compared to CDT\(^2\)
- Higher complete dissolution rate of thrombus\(^2\)
The EkoSonic® Endovascular System

106cm Working Length: Includes one 5.4 F infusion catheter (106cm long, 0.035 inch guidewire compatible) and one ultrasonic core matched to infusion length.

- 500-55106.................................................................6cm Treatment Zone
- 500-55112.................................................................12cm Treatment Zone
- 500-55118.................................................................18cm Treatment Zone
- 500-55124.................................................................24cm Treatment Zone
- 500-55130.................................................................30cm Treatment Zone
- 500-55140.................................................................40cm Treatment Zone
- 500-55150.................................................................50cm Treatment Zone

135cm Working Length: Includes one 5.4 F infusion catheter (135cm long, 0.035 inch guidewire compatible) and one ultrasonic core matched to infusion length.

- 500-56112.................................................................12cm Treatment Zone
- 500-56130.................................................................30cm Treatment Zone
- 500-56140.................................................................40cm Treatment Zone
- 500-56150.................................................................50cm Treatment Zone

All EKOS products are latex free.

Order Information:
Phone: 888-400-3567 or 425-415-3100
gFax: 425-415-3101
Email: CustomerService@ekoscorp.com
EKOS provides 24/7 helpline support.

Live Technical Support Helpline, available 24/7/365
Online Learning Center:  www.ekoscorp.com/learningcenter.htm

Contact Information:
Toll Free (in USA):  888-400-3567
Phone:  +1 425-415-3100
Fax:  +1 425-415-3101
Email:  CustomerService@ekoscorp.com

FDA CLEARED INDICATIONS: The EkoSonic® Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic® Endovascular System is intended for the infusion of solutions into the pulmonary arteries. The EkoSonic® Endovascular System is indicated for the ultrasound-facilitated, controlled and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism.

CONTRAINDICATIONS: Not designed for peripheral vasculature dilation purposes. The system is contraindicated when, in the medical judgement of the physician, such procedure may compromise the patient’s condition. See device instructions for use for complete prescribing information.

THE CE MARK (CE0086) HAS BEEN AFFIXED TO THE EKOSONIC® PRODUCT WITH THE FOLLOWING INDICATIONS:
Peripheral Vasculature: The EkoSonic® Endovascular Device, consisting of the Intelligent Drug Delivery Catheter (IDDC) and the MicroSonic™ Device (MSD), is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic® Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent.

Pulmonary Embolism: The EKOS EkoSonic® Endovascular System is intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25mmHg) or echocardiographic evaluation.

About EKOS®
EKOS Corporation, a BTG International group company, pioneered the development and clinical application of ultrasound infusion technologies in medicine, introducing its first system for the treatment of vascular thrombosis in 2005. Today, interventional radiologists, cardiologists, and cardiothoracic and vascular surgeons at leading institutions around the world use the EKOS® EkoSonic® Endovascular System to provide faster, safer and more complete dissolution of thrombus. To find out more about the EKOS® EkoSonic® Endovascular System, visit www.ekoscorp.com.

EKOS and EkoSonic are registered trademarks of EKOS Corporation, a BTG International group company. ‘Treat Smarter, Achieve More’ and ‘Acoustic Pulse Thrombolysis’ are trademarks of EKOS Corporation. ‘See More, Reach Further, Treat Smarter’ and ‘Imagine where we can go’ are trademarks of BTG International Ltd. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd elsewhere.

About BTG
BTG is a growing international specialist healthcare company that is developing and commercializing products targeting acute care, cancer and vascular diseases.

The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.

To find out more about the BTG International group companies and our products, visit www.btgplc.com.

© 2014 EKOS Corporation • US EKO-2014-0967